Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)COHEN, Roger B.Cancer treatment reviews. 2014, Vol 40, Num 4, pp 567-577, issn 0305-7372, 11 p.Article

New Agents in the Treatment for Malignancies of the Salivary and Thyroid GlandsMEHRA, Ranee; COHEN, Roger B.Hematology/oncology clinics of North America. 2008, Vol 22, Num 6, issn 0889-8588, xi, 1279-1295 [18 p.]Article

Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancerASTSATUROV, Igor; COHEN, Roger B; HARARI, Paul et al.Expert review of anticancer therapy. 2006, Vol 6, Num 9, pp 1179-1193, issn 1473-7140, 15 p.Article

A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neckBOWLES, Daniel W; SENZER, Neil; HAUSMAN, Diana et al.Investigational new drugs. 2014, Vol 32, Num 6, pp 1197-1203, issn 0167-6997, 7 p.Article

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral FormulationsDEES, E. Claire; COHEN, Roger B; MEHREN, Margaret Von et al.Clinical cancer research (Print). 2012, Vol 18, Num 17, pp 4775-4784, issn 1078-0432, 10 p.Article

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumorsHURWITZ, Herbert I; COHEN, Roger B; MCGOVREN, J. Patrick et al.Cancer chemotherapy and pharmacology. 2007, Vol 59, Num 1, pp 139-147, issn 0344-5704, 9 p.Article

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancerPOSNER, Marshall R; HERSHOCK, Diane M; MURPHY, Barbara A et al.The New England journal of medicine. 2007, Vol 357, Num 17, pp 1705-1715, issn 0028-4793, 11 p.Article

Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in lodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular ElementsHAYES, D. Neil; LUCAS, Amy S; HOSKINS, Janelle et al.Clinical cancer research (Print). 2012, Vol 18, Num 7, pp 2056-2065, issn 1078-0432, 10 p.Article

Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A KinaseCHAKRAVARTY, Arijit; SHINDE, Vaishali; ANDREU, Jordi et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 3, pp 675-685, issn 0008-5472, 11 p.Article

Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent AdenocarcinomaBURRIS, Howard A; ROSEN, Lee S; LEWIS, Nancy et al.Clinical cancer research (Print). 2010, Vol 16, Num 5, pp 1673-1681, issn 1078-0432, 9 p.Article

A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignanciesCOHEN, Roger B; AAMDAL, Steinar; NYAKAS, Marta et al.European journal of cancer (1990). 2013, Vol 49, Num 7, pp 1521-1529, issn 0959-8049, 9 p.Article

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer : Results From a Phase II StudyCOHEN, Ezra E. W; ROSEN, Lee S; TORTORICI, Michael et al.Journal of clinical oncology. 2008, Vol 26, Num 29, pp 4708-4713, issn 0732-183X, 6 p.Article

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced CancersADJEI, Alex A; COHEN, Roger B; MALONEY, Lara et al.Journal of clinical oncology. 2008, Vol 26, Num 13, pp 2139-2146, issn 0732-183X, 8 p.Article

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)COHEN, Roger B; LANGER, Corey J; HEALEY, Diane et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 1, pp 81-89, issn 0344-5704, 9 p.Article

Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studiesKRAMER, Noel M; HORWITZ, Eric M; LANGER, Corey J et al.Head & neck. 2005, Vol 27, Num 5, pp 406-414, issn 1043-3074, 9 p.Article

Targeting signal transduction pathways in colorectal cancer-more than skin deepCOHEN, Steven J; COHEN, Roger B; MEROPOL, Neal J et al.Journal of clinical oncology. 2005, Vol 23, Num 23, pp 5374-5385, issn 0732-183X, 12 p.Article

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumorsVON MEHREN, Margaret; BRITTEN, Carolyn D; LEONG, Stephen et al.Investigational new drugs. 2014, Vol 32, Num 3, pp 518-525, issn 0167-6997, 8 p.Article

A Web-Based Communication Aid for Patients with Cancer: The CONNECT StudyMEROPOL, Neal J; EGLESTON, Brian L; FLEISHER, Linda et al.Cancer. 2013, Vol 119, Num 7, pp 1437-1445, issn 0008-543X, 9 p.Article

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid CancerKURZROCK, Razelle; SHERMAN, Steven I; HONG, David S et al.Journal of clinical oncology. 2011, Vol 29, Num 19, pp 2660-2666, issn 0732-183X, 7 p.Article

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer PatientsKOCH, Kevin M; REDDY, Nandi J; COHEN, Roger B et al.Journal of clinical oncology. 2009, Vol 27, Num 8, pp 1191-1196, issn 0732-183X, 6 p.Article

Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced CancersLEWIS, Nancy L; LEWIS, Lionel D; EDER, Joseph P et al.Journal of clinical oncology. 2009, Vol 27, Num 31, pp 5262-5269, issn 0732-183X, 8 p.Article

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancerJÄNNE, Pasi A; VON PAWEL, Joachim; DASSE, Kathy et al.Journal of clinical oncology. 2007, Vol 25, Num 25, pp 3936-3944, issn 0732-183X, 9 p.Article

Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinomaSANTEN, Richard J; PETRONI, Gina R; FISCH, Michael J et al.Cancer. 2001, Vol 92, Num 8, pp 2095-2101, issn 0008-543XArticle

Clinical Responses to Selumetinib (AZD6244; ARRY-142886)-Based Combination Therapy Stratified by Gene Mutations in Patients With Metastatic MelanomaPATEL, Sapna P; LAZAR, Alexander J; KIM, Kevin B et al.Cancer. 2013, Vol 119, Num 4, pp 799-805, issn 0008-543X, 7 p.Article

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G₁ Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2SPRATLIN, Jennifer L; COHEN, Roger B; MEROPOL, Neal J et al.Journal of clinical oncology. 2010, Vol 28, Num 5, pp 780-787, issn 0732-183X, 8 p.Article